Back to top
Send SMS Send Inquiry
+918035918946
Fenofibrate API Fenofibrate API

Fenofibrate API

1850 INR/Kilograms

Product Details:

  • Solubility DMSO
  • Molecular Formula C20H21ClO4
  • HS Code 029
  • Taste Odorless
  • Smell Other
  • Melting Point 80 degree
  • Form Powder
  • Supply Ability : 1000 Kilograms Per Month
  • Click to view more
X

Price And Quantity

  • 1850 INR/Kilograms
  • 25KG Kilograms
  • 1800.00 - 1900.00 INR/Kilograms

Product Specifications

  • 360.83
  • 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methyl-propanoic Acid 1-Methylethyl Ester
  • 49562-28-9
  • Powder
  • Medicine Grade
  • Other
  • 80 degree
  • Odorless
  • Pharmaceutical
  • DMSO
  • C20H21ClO4
  • hypercholesterolemia or mixed dyslipidemia
  • 029

Trade Information

  • Cash Advance (CA)
  • 1000 Kilograms Per Month
  • 15 Days
  • Yes
  • Free samples are available
  • 25kg drum packing
  • Africa, Middle East, Western Europe, Asia
  • West Bengal, Uttarakhand, Uttar Pradesh, Tripura, Telangana, Tamil Nadu, Sikkim, Rajasthan, Pondicherry, Punjab, Odisha, Nagaland, Manipur, Meghalaya, Mizoram, Maharashtra, Madhya Pradesh, Lakshadweep, Kerala, Karnataka, Jharkhand, Jammu and Kashmir, Himachal Pradesh, Haryana, Goa, Gujarat, Daman and Diu, Dadra and Nagar Haveli, Delhi, Chandigarh, Chhattisgarh, Bihar, Arunachal Pradesh, Assam, Andhra Pradesh, Andaman and Nicobar Islands, West India, East India, North India, Central India, South India, All India,

Product Description

 Fenofibrate is an oral medication of the fibrate class used to treat abnormal blood lipid levels.It is less preferred to statin medications as it does not appear to reduce the risk of heart disease or death.Its use is recommended together with dietary changes.

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate reduces risk and progression of diabetic retinopathy in type 2 diabetic patients. It was initially indicated for diabetic retinopathy in patients with type 2 diabetes and diabetic retinopathy in Australia. The large scale, international FIELD and ACCORD-Eye trials found that fenofibrate therapy reduced required laser treatment for diabetic retinopathy by 31%, as well as reducing progression by 3.7% over 4 years.Although no statistically significant cardiovascular risk benefits were identified in these trials, benefits may accrue to add on therapy to patients with high triglyceride dyslipidaemia currently taking statin medications.

Fenofibrate appears to reduce the risk of below ankle amputations in patients with Type 2 diabetes without microvascular disease. The FIELD study reported that fenofibrate at doses of 200mg daily, reduced the risk for any amputation by 37% independent of glycaemic control, presence or absence of dyslipidaemia and its lipid-lowering mechanism of action.However, the cohort of participants who underwent amputations were more likely to have had previous cardiovascular disease (e.g. anginamyocardial infarction), longer duration of diabetes and had baseline neuropathy.

Fenofibrate has an off-label use as an added therapy of high blood uric acid levels in people who have gout.

It is used in addition to diet to reduce elevated low-density lipoprotein cholesterol (LDL), total cholesteroltriglycerides (TG), and apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL) in adults with primary hypercholesterolemia or mixed dyslipidemia


CANOPY ENTERPRISE

* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



Most Popular Products
Alpha Blue
Sulfamic Acid
Activated Carbon
Potassium Chloride